SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

Market participants are fixated on rising geopolitical tensions following a 48-hour ultimatum regarding the Strait of Hormuz, sparking concerns over global energy supply and inflationary pressures. The community is actively debating the potential for a rapid military de-escalation versus the risk of a broader economic shock, while institutional hedging and extreme volatility have triggered widespread calls for caution.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

SPDR Gold Shares (GLD) is experiencing intense volatility and downward pressure as investors abandon the metal amid a strengthening dollar and surging bond yields. The community is sharply divided, with many debating whether this is a structural failure of gold's safe-haven narrative or a massive liquidity flush offering a generational buying opportunity.

AleAnna, Inc. operates as a technology-driven energy company, which engages in supplying low-carbon natural gas and renewable natural gas to Italy. The company was founded in 2007 and is headquartered in Dallas, TX.

AleAnna Inc. - Ordinary Shares - Class A

AleAnna Inc. is surging due to intense market focus on natural gas supply disruptions caused by the recent conflict in the Middle East, which has elevated the stock's status as a key play for European energy security. The community is actively discussing a potential short squeeze fueled by massive trading volume and extremely limited share availability for borrowing, with many traders drawing parallels to previous parabolic runs in the energy sector.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

Market participants are reacting to heightened geopolitical tensions in the Middle East, specifically the escalating rhetoric between the U.S. and Iran following a 48-hour ultimatum regarding the Strait of Hormuz. Community discussion is dominated by concerns over potential energy supply disruptions, fears of a broader conflict impacting global infrastructure, and speculation on how these macro events will influence the trajectory of tech-heavy indices.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is currently drawing intense investor focus as it navigates significant volatility, driven by a blend of technical selling, ongoing geopolitical tensions impacting energy markets, and skepticism regarding the ambitious 'Terafab' chip manufacturing initiative. The community is deeply divided, with bulls pointing to the company's long-term potential in AI and robotics, while bears are highlighting disappointing financial performance and legal scrutiny regarding past statements.

ProShares Trust - ProShares UltraPro Short QQQ -3x Shares

ProShares UltraPro Short QQQ

Investors are actively debating the sustainability of the current AI-led market rally, with many using SQQQ as a strategic hedge against geopolitical instability in the Middle East and concerns over stretched equity valuations. Community sentiment is deeply divided between those betting on an imminent market pullback due to economic cooling and those wary of the structural decay risks inherent in holding inverse leveraged ETFs for the long term.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), and Global Services (BGS). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The company was founded by William Edward Boeing on July 15, 1916, and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

Boeing is trending as investors react to news of a manufacturing flaw involving wiring issues on certain 737 MAX jets, which has temporarily slowed deliveries. While the company maintains that the repairs are minor and will not impact long-term production targets, the community remains divided between those viewing the pullback as a buying opportunity given the strong commercial backlog and those concerned about persistent quality control challenges.

VanEck ETF Trust - VanEck Gold Miners ETF

VanEck Gold Miners ETF

VanEck Gold Miners ETF (GDX) is facing intense volatility as the precious metals sector undergoes a sharp correction, fueled by a strengthening U.S. dollar, rising treasury yields, and a broader market reassessment of the gold-as-a-safe-haven narrative amid Middle Eastern tensions. While some investors are treating the pullback as an accumulation opportunity, the community is actively debating whether the recent steep drawdown represents a structural change or a temporary flush of overleveraged positions before a potential recovery.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending as investors weigh strong China smartphone sales against broader market concerns over stagflation, geopolitical volatility in the Middle East, and the potential impact of interest rate uncertainty on tech valuations. While some in the community highlight the firm's resilient hardware ecosystem and AI-driven growth potential, many are actively debating the stock's recent underperformance and technical breakdown, with traders focused on critical support levels near the 200-day moving average.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund (USO) is trending as geopolitical volatility in the Middle East intensifies following a high-stakes 48-hour ultimatum by the U.S. regarding the Strait of Hormuz. The community is actively debating whether energy prices will continue to spike due to potential supply infrastructure disruptions or if the market has already reached a short-term peak as diplomatic chatter and military deployment news create deep uncertainty.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Penny Stocks To Research - March 22nd

Kosmos Energy, Co-Diagnostics, SELLAS Life Sciences Group, JetBlue Airways, BigBear.ai, Banco Bradesco, and Bitfarms are the seven Penny stocks to watch today, according to MarketBeat's stock screener tool. Penny stocks are shares of very small companies that trade at low pricestypically under $5...

Penny Stocks To Watch Now - March 21st

Kosmos Energy, Co-Diagnostics, SELLAS Life Sciences Group, JetBlue Airways, and BigBear.ai are the five Penny stocks to watch today, according to MarketBeat's stock screener tool. Penny stocks are...

<ul class="summary-bullets"><li>Both SLS009 and Galinpepimut-S are designed to address different stages of acute myeloid leukemia.</li><li>Alliance Global said the updates on SLS009 and GPS strengthen the investment thesis for the company’s pipeline.</li><li>SLS009 is being tested in early-stage acute myeloid leukemia, showing promising effectiveness and tolerability in patients.</li></ul>Alliance Global has increased its price target for Sellas Life Sciences (SLS) shares to $10 from $7.50, maintaining a ‘Buy’ rating after the biotech firm shared progress updates on its clinical-stage treatments.The new price target implies a potential 92% upside to the stock’s closing price on Thursday. The firm’s optimism comes as Sellas Life Sciences detailed developments for its two leading candidates, SLS009 and Galinpepimut-S.<h2 class="st-heading-2">Clinical Advancements Highlight Potential</h2>Both SLS009 and Galinpepimut-S are designed to address different stages of acute myeloid leukemia (AML) in patients. Alliance Global said that these updates strengthen the investment thesis for the company’s pipeline, offering potential upside for shareholders, according to TheFly.&nbsp;LS009 is currently in clinical testing for patients in the initial phases of acute myeloid leukemia, with the company reporting encouraging signs of efficacy and tolerability. The therapy is being closely watched as a potential new treatment avenue for patients with limited options.On Tuesday, Sellas announced that preclinical data for its CDK9 inhibitor, SLS009 (tambiciclib), will be presented in a poster session at the American Association for Cancer Research (AACR) conference, April 17–22 in San Diego.<a href="https://stocktwits.com/symbol/SLS">Sellas Life Sciences' stock</a> traded over 5% higher on Friday morning. Retail sentiment on Stockwtits around the stock remained in ‘bearish’ territory amid ‘low’ message volume levels.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_03_20_104016_png_a1cf576a4e.webp" alt="SLS’s Sentiment Meter and Message Volume as of 10:15 a.m. ET on Mar. 20, 2026 | Source: Stocktwits" width="931" height="98"><figcaption>SLS’s Sentiment Meter and Message Volume as of 10:15 a.m. ET on Mar. 20, 2026 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Galinpepimut-S Focuses On Advanced Patients</h2>Galinpepimut-S is aimed at individuals with more progressed disease. Early trial results suggest it could complement existing therapies, providing a targeted immunotherapy approach.&nbsp;<blockquote>“We are advancing toward the final analysis of our Phase 3 REGAL trial evaluating GPS in AML patients who have achieved complete remission following second-line salvage therapy.”— Angelos Stergiou, President And CEO, Sellas Life Sciences</blockquote>The trial will conduct its final analysis after 80 survival events; as of Dec. 26, 2025, 72 events occurred, with the study still blinded, pending database lock, analysis, and topline results release.SLS stock has gained over 43% year-to-date.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/smcx-etf-plummets-55-as-super-micro-legal-troubles-and-export-violations-weigh-on-investor-sentiment/cZ3XAV4RILj">SMCX ETF Plummets 55% As Super Micro Legal Troubles And Export Violations Weigh On Investor Sentiment</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A researcher works in the clinical-stage biopharmaceutical company Xencors new laboratory in Pasadena.

SLS Stock In Focus As Alliance Global Sees 92% Upside Following AML Trial Updates

The company will present preclinical data on SLS009 in a poster session at the American Association for Cancer Research.

Equity

The company will present preclinical data on SLS009 in a poster session at the American Association for Cancer Research.


SELLAS Life Sciences Group (NASDAQ:SLS) Shares Gap Up on Earnings Beat

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Gap Up Following Better-Than-Expected Earnings...

<ul class="summary-bullets"><li>Net loss in FY25 narrowed to $26.9 million from $30.9 million a year ago, with R&amp;D costs falling to $16 million.</li><li>Phase 3 Regal AML trial nears final analysis, with 72 of 80 required survival events reached, keeping focus on upcoming topline data.</li><li>SLS009 advances into first-line AML trials, backed by prior 46% response rate data and supported by upcoming AACR preclinical results.</li></ul>Shares of Sellas Life Sciences Group Inc. (SLS) posted modest gains in extended trading on Thursday after the company reported a narrower full-year loss and a stronger cash position, as investors turned their focus to a closely watched Phase 3 AML trial nearing its final trigger.<a href="https://stocktwits.com/symbol/SLS">SLS stock</a> snapped three straight sessions of losses on Thursday to end 5% higher at $5.20,&nbsp;and gained 0.4% in the extended session. However, shares are headed for their worst week in over a month.<h2 class="st-heading-2">SLS FY25 Review</h2>The biotech firm reported a net loss of $26.9 million, or $0.25 per share, for the year ended Dec. 31, 2025, compared with a net loss of $30.9 million, or $0.5 per share, in 2024. Research and development expenses declined to $16 million from $19.1 million, while general and administrative expenses were largely unchanged at $12.3 million.The decline in expenses was primarily driven by lower clinical trial and regulatory consulting costs following the completion of enrollment in the Phase 3 Regal study in early 2024. Sellas also reported receiving $67.2 million in gross proceeds from warrant exercises during 2025.Sellas ended 2025 with $71.8 million in cash and cash equivalents and said it received an additional $42.6 million in proceeds from warrant exercises in the first quarter of 2026.&nbsp;“With a catalyst rich outlook, continued clinical execution, our strongest financial position in history, and expansion into earlier treatment settings, we look forward to an important year ahead,” CEO Angelos Stergiou said in a statement.Sellas said 2026 is shaping up to be a “pivotal year,” citing progress across its acute myeloid leukemia (AML) programs and upcoming catalysts.<h2 class="st-heading-2">GPS Trial Moves Closer To Final Analysis</h2>Investor attention remains centered on Sellas’ Phase 3 Regal trial evaluating galinpepimut-S (GPS) in AML patients who have achieved remission following second-line salvage therapy.The event-driven trial is designed to trigger&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sls-stock-falls-premarket-investors-cautious-as-aml-trial-readout-nears/cZdVgoyRIId">final analysis</a> upon reaching 80 survival events. The company said 72 events had been recorded as of Dec. 26, with the study remaining fully blinded. Once the required event threshold is reached, Sellas will proceed with database lock, statistical analysis, unblinding and disclosure of topline results.<h2 class="st-heading-2">Sellas Builds Momentum With SLS009 Pipeline</h2>The company also highlighted its second pipeline candidate, SLS009, which is being advanced into earlier lines of treatment, with the first patient already dosed in an 80-patient Phase 2 trial in newly diagnosed AML.In January, Sellas entered a collaboration with Impact-AML to advance the program in Europe, with a study expected to enroll around 40 patients starting in the second quarter.The program builds on previously reported Phase 2 data, where SLS009, used alongside azacitidine and venetoclax, two commonly used AML therapies, achieved a 46% response rate in relapsed or hard-to-treat AML, including 29% complete responses, with improved survival and no dose-limiting toxicities observed.<h2 class="st-heading-2">Sellas Flags ‘Compelling’ Early Data For SLS009</h2>The company also pointed to preclinical findings supporting SLS009, with data to be presented at the American Association for Cancer Research (AACR)&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sls-stock-potent-aml-drug-data-aacr-cancer-summit-momentum/cZ37TBERIg5">next month</a>, showing the drug induces cancer cell death in AML models, including those with high-risk ASXL1 and TP53 mutations, with early changes seen in key survival proteins such as MCL-1 and survivin.The presentation comes ahead of earlier preclinical results shared at the European Society for Medical Oncology Congress, where SLS009 showed a statistically significant survival benefit in a T-cell leukemia model, both as a standalone therapy and in combination with venetoclax.Stergiou called the findings “compelling new data,” adding that SLS009 showed activity in AML models with high resistance.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for SLS was ‘bearish’ amid ‘low’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/sls_ss_png_089ae693bf.webp" alt="sls ss.png" width="967" height="141"><figcaption>SLS sentiment and message volume as of March 19 | Source: Stocktwits</figcaption></figure>One user said the stock’s direction largely depends on the upcoming GPS data, with strong results potentially driving sharp gains and weaker outcomes posing downside risk.<stembedurl>https://stocktwits.com/Andi77/message/648041521</stembedurl>Another user said, “THE DATA JUST NEED TO BE “GOOD ENOUGH” (HR 0.636) TO GET FDA APPROVAL. SO IT IS EITHER $70 OR $180.”<stembedurl>https://stocktwits.com/Duncan74/message/648045039</stembedurl>SLS stock has rocketed over 300% over the past year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

SLS stock has rocketed over 300% over the past year. (Photo credit: Getty Images)

SLS Stock Pops After-Hours As Loss Shrinks, Cash Swells — All Eyes On High Stakes AML Trial In 'Pivotal' 2026

The company’s cash stood at $71.8 million at the end of the year, marking the company’s strongest balance sheet so far.

SELLAS Life Sciences Group (NASDAQ:SLS) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS

SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) posted its earnings results on Thursday. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.01...

<ul class="summary-bullets"><li>The company flagged “potent” preclinical data for its AML drug SLS009 ahead of the AACR 2026 conference.</li><li>CEO Angelos Stergiou called the findings “compelling,” highlighting activity even in high-risk AML mutations like ASXL1 and TP53.</li><li>Sellas recently enrolled its first patient in a Phase 2 AML trial, targeting hard-to-treat groups.</li></ul>Shares of Sellas Life Sciences Group, Inc. (SLS) jumped nearly 6% in overnight trading on Wednesday after the company flagged “potent” new preclinical data for its acute myeloid leukemia (AML) drug SLS009, with the findings set to be unveiled at a cancer conference next month.<a href="https://stocktwits.com/symbol/SLS">SLS stock</a> recorded its second straight session of losses on Tuesday, declining nearly 6% to $5.04.<h2 class="st-heading-2">CEO Flags ‘Compelling’ SLS009 Findings</h2>The company said it will present the data at the American Association for Cancer Research (AACR) 2026 in San Diego, drawing investor focus to its advancing acute myeloid leukemia (AML) program.Sellas said early lab data show that SLS009 helps drive leukemia cells toward self-destruction by blocking the signals that normally keep them alive, including proteins such as MCL-1 and Survivin.The company said the drug increased caspase-3 levels, a key indicator that cancer cells are dying, while lowering MCL-1. With repeated dosing, the drug became more effective, with its potency improving significantly over time and its effects becoming stronger the longer it was used.In a&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.linkedin.com/feed/update/urn:li:activity:7439771995292057600/?originTrackingId=6fSXlWZTuGLQXVW%2B%2FbRQyg%3D%3D">LinkedIn Post</a> late Monday, CEO Angelos Stergiou said the findings represent “compelling new data,” adding that SLS009 has shown the ability to deliver potent activity even in AML models with high resistance, including those with ASXL1 and TP53 mutations.<h2 class="st-heading-2">Clinical Momentum Builds For SLS009</h2>The update comes days after Sellas announced the&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sls-stock-in-spotlight-first-aml-patient-enrolled-in-phase-2-leukemia-trial/cZduE6RRI9L">first patient</a> enrollment in its Phase 2 trial evaluating SLS009 in newly diagnosed AML patients. The study is expected to enroll around 80 patients across the U.S. and Europe, targeting individuals unlikely to benefit from standard therapies such as Venetoclax and Azacitidine, as well as those showing early resistance.The trial builds on prior Phase 2 results in relapsed or refractory AML, where SLS009, in combination therapy, delivered overall response rates of up to 50% in certain subgroups, with favorable safety and tolerability. Topline data from the ongoing trial is expected in the fourth quarter.<h2 class="st-heading-2">GPS Phase 3 Trial Nears Key Readout</h2>Investor attention is also focused on Sellas’ lead immunotherapy,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sls-stock-falls-premarket-investors-cautious-as-aml-trial-readout-nears/cZdVgoyRIId">GPS (Galinpepimut-S)</a>, which is currently being evaluated in a late-stage Phase 3 trial.The event-driven Regal study is approaching its final analysis trigger, with 72 of 80 required survival events already recorded. The trial is designed to assess whether GPS can improve overall survival in AML patients in remission.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for SLS was ‘bearish’ amid ‘normal’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/sls_ss_png_0f6aedd38a.webp" alt="sls ss.png" width="966" height="141"><figcaption>SLS sentiment and message volume as of March 18 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/BIOTECH_GURU/message/647821612">said</a>, “Ignoring the noise and waiting for a news drop when it happens. The longer we wait the higher likelihood of overwhelmingly positive results.”&nbsp;<stembedurl>https://stocktwits.com/BIOTECH_GURU/message/647821612</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/Johnmtnb2018/message/647821213">said</a>, “Crazy Action Overnight $5.80. Something Bigly Positive gps regal p3 news coming!”<stembedurl>https://stocktwits.com/Johnmtnb2018/message/647821213</stembedurl>SLS stock has surged over 300% over the past year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

SLS stock has surged over 300% over the past year. (Photo credit: Getty Images)

SLS Stock Jumps Overnight: ‘Potent’ AML Drug Data Ahead Of Cancer Summit Fuels Fresh Momentum

Shares of Sellas Life Sciences Group, Inc. (SLS) jumped nearly 6% in overnight trading on Wednesday after the company flagged “potent” new preclinical data for its acute myeloid leukemia (AML) drug SLS009

Investors are also watching the late-stage GPS immunotherapy trial, which is nearing final analysis with 72 of 80 survival events recorded.

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Down 5.3% - Here's Why

SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Down 5.3% - What's Next...

SELLAS Life Sciences Group (NASDAQ:SLS) Trading 9.3% Higher - What's Next?

SELLAS Life Sciences Group (NASDAQ:SLS) Trading Up 9.3% - Time to Buy...

<ul class="summary-bullets"><li>The study focuses on patients unlikely to benefit from&nbsp;azacitidine/venetoclax or showing early resistance.</li><li>SLS009 showed strong Phase 2 results in relapsed/refractory AML, surpassing 20% overall response rate.</li><li>Topline data for the trial is expected by Q4 2026.</li></ul>SELLAS Life Sciences Group, Inc. (SLS) on Thursday said it has enrolled its first patient in a Phase 2 trial of SLS009 (tambiciclib), a selective CDK9 inhibitor for patients with acute myeloid leukemia (AML).&nbsp;The trial aims to assess efficacy in first-line AML treatment and will enroll approximately 80 patients across two high-need cohorts.<h2 class="st-heading-2">Trial Design and Technology Integration</h2>The study, identified as NCT04588922, targets patients predicted to respond poorly to standard azacitidine/venetoclax (aza/ven) therapy based on molecular profiling, as well as those who show early resistance after two treatment cycles.<blockquote>“By targeting molecularly defined subgroups and those demonstrating early non-response, we aim to address a critical need in frontline AML and position SLS009 for potential registrational development.”-Angelos Stergiou, President and CEO, SELLAS</blockquote>Following the update,&nbsp;<a href="https://stocktwits.com/symbol/SLS">SELLAS Life Sciences stock</a> traded over 1% higher in Thursday’s premarket.&nbsp;SLS009 previously demonstrated promising results in relapsed/refractory AML, exceeding the 20% overall response rate (ORR) threshold in Phase 2 studies. Notably, patients receiving the recommended 30 mg twice-weekly dose achieved an overall ORR of 40%.<h2 class="st-heading-2">Study Timeline And Global Reach</h2>The trial is planned across sites in the United States and Europe, with topline data expected by Q4 2026. By expanding SLS009 into newly diagnosed AML populations, SELLAS aims to broaden its therapeutic impact beyond relapsed/refractory cases, aligning with FDA guidance.If successful, SLS009 could offer a new targeted option for patients with limited treatment prospects, particularly those with predictive biomarkers indicating poor response to conventional therapies.<h2 class="st-heading-2">What Are Stocktwits Users Saying?</h2>On Stocktwits, retail sentiment around the stock remained in ‘bullish’ territory amid ‘high’ message volume levels.&nbsp;A bullish Stocktwits user expressed optimism about the trial.&nbsp;<stembedurl>https://stocktwits.com/peacewealth7447/message/647325822</stembedurl>Another user called the stock ‘safest investment’.&nbsp;<stembedurl>https://stocktwits.com/samsha1/message/647326354</stembedurl>SLS stock has gained 358% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/orbs-stock-shoots-up-125-m-backing-bitmine-ark-invest-payward-dan-ives-perfect-team/cZdu34jRI9W">ORBS Stock Shoots Up 35% After $125M Backing From Bitmine, ARK Invest, And Payward – Dan Ives Calls It 'Perfect Team'</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

ProKidney (PROK) is developing rilparencel, an autologous cellular therapy aimed at slowing kidney function decline in patients with chronic kidney disease/ Photo credit: Getty Images

SLS Stock In Spotlight: First AML Patient Enrolled In Phase 2 Leukemia Trial

The study aims to evaluate SLS009’s effectiveness in a molecularly defined cohort of frontline leukemia patients, enrolling approximately 80 patients across two high-priority groups.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Strategic institutional positioning and new banking ties suggest a high-level corporate buyout is moving toward completion.

Investors are laser-focused on upcoming Phase 3 readout results as the primary driver for a potential valuation breakout.

Significant volume on the tape is interpreted by traders as the clearing of legacy warrants, removing technical supply pressure.

Debates rage between bulls and bears over whether aggressive ATM activity and volume shifts indicate dilution or expert maneuvering.

Current Price	$5.41
Prev Close	$5.20
Open	$5.55
Dividend Yield	0.00%
50-Day Moving Average	$4.44
Beta	0.71
Avg. Volume	5.84M
PE Ratio	-19.36

52-Week High	$6.14
52-Week Low	$0.9516
Market Capitalization	$854.81M
EPS (Annual)	-$0.2463
Price to Book	10.28
Revenue Per Employee	$0.00

SLS
SELLAS Life Sciences Group Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SLS News

SLSSELLAS Life Sciences Group Inc